May 2013

Contents

Editorial

• Volume 14 Number 5/6 May/June 2013

Conference reports

• 14th International Workshop on Clinical Pharmacology, 22-24 April 2013, Amsterdam

• Population pharmacokinetics of efavirenz to inform dosing in children three months of age and above

• Bilirubin as a surrogate marker for atazanavir in children

• Transplacental transfer of atazanavir and neonatal hyperbilirubinaemia

• Tenofovir population pharmacokinetics in pregnancy

• Effect of rifampicin on BMS-663068 in HIV negative volunteers

• Coformulated darunavir/cobicistat: an alternative to separate ritonavir boosting

• Continuous infusion of T-20 in multidrug resistant patient with intolerance of s.c. injections

• 20th Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2013, Atlanta

• Small increase in birth defects in the French Perinatal Cohort

• Uptake and retention in Malawi’s Option B+ programme

• Optimising ART initiation in pregnancy through linkage of services vs integration of ART into antenatal care

• Cardiovascular disease and other non-AIDS defining events

• Dramatic advances at CROI for HCV treatment: telaprevir, boceprevir, faldaprevir, sofosbuvir, ABT-450, ABT-267, ABT-333 and ledipasvir

• Basic research highlights from CROI 2013

• Probiotic/prebiotic supplement combination shows benefits in SIV-infected pigtailed macaques

Antiretrovirals

• EU approves four-in-one Stribild

• FDA delays decision for elvitegravir and cobicistat

• EU approval for raltegravir in children aged 2 years and older

• FDA update label for paediatric efavirenz and capsule sprinkle formulation

• Cobicistat compared to ritonavir to boost atazanavir in treatment naive patients

Treatment access

• Upcoming WHO ART guidelines (2013)

• Fixed dose combination efavirenz/tenofovir/FTC for South Africa

• New UNAIDS report highlights progress in the AIDS response in Africa

• Indian Supreme Court delivers verdict in Novartis case: decision safeguards access to affordable medicines and prevents abusive patenting of medicines

• FDA approval of generic ARVs

Side effects

• Osteonecrosis in HIV positive patients is associated with increased levels of CRP and D-dimer

• No impact of ART on progression or regression of anal squamous intraepithelial lesions

• Incidence of cancers in Australian observational cohort

Cure-related research

• Searching for HIV in Timothy Brown, the Berlin Patient

• Reviewing strategies for draining HIV reservoirs

Basic science and immunology

• Can a route to broadly neutralising antibodies be traced?

Other news

• Life insurance for HIV positive people on stable treatment

On the web

• Conference abstract: BHIVA 2013

• PLoS Medicine
: free full text online articles

PDFs

• Volume 14 Number 5/6 May/June 2013 PDF